Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. [electronic resource]
Producer: 20111212Description: 2201-7 p. digitalISSN:- 1569-8041
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Aromatase Inhibitors -- administration & dosage
- Breast Neoplasms -- drug therapy
- Chemotherapy, Adjuvant
- Double-Blind Method
- Drug Administration Schedule
- ErbB Receptors -- biosynthesis
- Female
- Humans
- Ki-67 Antigen -- biosynthesis
- Letrozole
- Middle Aged
- Nitriles -- administration & dosage
- Prognosis
- Receptors, Estrogen -- biosynthesis
- Receptors, Progesterone -- biosynthesis
- Tamoxifen -- administration & dosage
- Triazoles -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.